Placebo for Budigalimab (ABBV-181) - 0.9% Sodium Chloride or DILUENT clinical trials

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-controlled Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics of Budigalimab and/or ABBV-382 in People Living with HIV on Stable Antiretroviral Therapy Undergoing Analytical Treatment Interruption.

This study looks at new medicines (Budigalimab and ABBV-382) for people with HIV. It tests if these medicines can help control HIV without daily treatment, by carefully pausing regular medication. The goal is to see if HIV stays low after stopping usual drugs.